V-Strant

V-Strant 50mg Injection is a medication used to treat advanced breast cancer in postmenopausal women. Here are some key points about the product:

Composition:

V-Strant 50mg Injection contains Fulvestrant, a selective estrogen receptor degrader (SERD).

Indications:

V-Strant 50mg Injection is indicated for the treatment of:

1. Advanced hormone-receptor-positive breast cancer in postmenopausal women
2. Advanced breast cancer that has progressed on or after prior endocrine therapy

Mechanism of Action:

Fulvestrant works by:

1. Binding to the estrogen receptor (ER) and promoting its degradation
2. Reducing the levels of estrogen receptors in the cancer cells
3. Inhibiting the growth and proliferation of cancer cells

Dosage and Administration:

The recommended dosage of V-Strant 50mg Injection is:

• 50mg administered as an intramuscular injection every 14 days
• Administered in a healthcare setting under the supervision of a healthcare professional

Side Effects:

Common side effects of V-Strant 50mg Injection include:

1. Hot flashes
2. Nausea and vomiting
3. Fatigue
4. Joint pain
5. Muscle pain
6. Increased risk of infections

Serious side effects can include:

1. Arterial thromboembolism (blood clots)
2. Cardiac arrest
3. Pulmonary embolism
4. Neurological events (e.g., stroke, seizures)

Contraindications:

V-Strant 50mg Injection is contraindicated in patients with:

1. Hypersensitivity to Fulvestrant
2. Pregnancy or breastfeeding
3. Active bleeding or a history of gastrointestinal perforation

Precautions:

1. Patients with a history of cardiovascular disease or stroke should be closely monitored while receiving V-Strant 50mg Injection.
2. Patients with a history of thromboembolic events should be closely monitored while receiving V-Strant 50mg Injection.
3. Patients with a history of liver disease or liver impairment should be closely monitored while receiving V-Strant 50mg Injection.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of hot flashes, nausea, or vomiting.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store refrigerated at 2°C to 8°C (36°F to 46°F).
• Do not freeze or expose to direct sunlight.
• Use within 24 hours of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.